… machinery. Axiomer® RNA editing technology harnesses ADAR(Adenosine Deaminase Acting on RNA), which is machinery … recruiting endogenously expressed enzymes to make precise adenine-to-inosine (A-to-I) or uridine-to-pseudouridine …
… machinery. Axiomer® RNA editing technology harnesses ADAR(Adenosine Deaminase Acting on RNA), which is machinery … with wet-lab scientists, technicians, project leads. Skills and competencies that are required for making …
… machinery. Axiomer® RNA editing technology harnesses ADAR(Adenosine Deaminase Acting on RNA), which is machinery … designing and implementing a new product planning process Leads new product planning, positioning, and pre-launch …
… machinery. Axiomer® RNA editing technology harnesses ADAR(Adenosine Deaminase Acting on RNA), which is machinery … team in Leiden. The Senior Scientist Bioinformatics will lead bioinformatics activities that support the wet-lab …
Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further momentum toward the clinicAccelerated development of Axiomer™ for CNS ap
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early 2025
Axiomer activity demonstrated across multiple preclinical in vitro
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas
Stre
Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight dataMartin Maier, PhD nominated to Board with Annual General